Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Researchers in South Korea have developed an organoid disease model and non-destructive stiffness analysis technology for ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

A protein that stops cells from dividing in response to damage or stress could be a new biomarker or therapeutic target for ...

On this World Liver Day, the message is clear: protecting your liver begins with a closer look at your plate—and your glass.